Cargando…
Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
The 5-year survival rate of patients with extensive-stage small cell lung cancer (ES-SCLC) is <8%; therefore there is an urgent need for more effective treatment. Although immune checkpoint inhibitors have been widely used to treat lung cancer, the efficacy of anti-programmed death 1 therapy for...
Autores principales: | Wu, Ying, Chen, Yinqiao, Yang, Zhouliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236139/ https://www.ncbi.nlm.nih.gov/pubmed/37273750 http://dx.doi.org/10.3892/etm.2023.12012 |
Ejemplares similares
-
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023) -
Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report
por: Huang, Fengxiang, et al.
Publicado: (2022) -
Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021) -
Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022) -
Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
por: Li, Yong, et al.
Publicado: (2022)